TEGSEDI - Approved hATTR Treatment in Canada  - $0.00 CAD Listing ID: 185397

     Other Actions


         Poster Info


Classified Info

Listing Began: May 31
Number of times Viewed: 66


Health Canada approved Tegsedi as the first treatment for polyneuropathy in adult patients with hATTR amyloidosis. It is a transthyretin-directed antisense oligonucleotide drug designed to reduce the production of TTR by binding to the messenger RNA (mRNA), leading to the reduction of serum TTR and TTR deposits in tissues.
For Tegsedi prescribing information visit website.

Ottawa Region Ontario Canada